Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 2
1976 1
1977 1
1978 1
1979 2
1982 1
1983 2
1984 2
1985 7
1986 4
1987 11
1988 4
1989 7
1990 1
1991 5
1992 3
1993 7
1994 3
1995 4
1996 4
1997 8
1998 2
1999 1
2000 5
2002 5
2003 7
2004 1
2005 3
2006 4
2007 4
2008 8
2009 4
2010 3
2011 6
2012 5
2013 4
2014 4
2015 13
2016 8
2017 5
2018 9
2019 1
2020 7
2021 5
2022 9
2023 7
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

202 results

Results by year

Filters applied: . Clear all
Page 1
Pathogenesis and management of accelerated and blast phases of chronic myeloid leukemia.
Senapati J, Jabbour E, Kantarjian H, Short NJ. Senapati J, et al. Leukemia. 2023 Jan;37(1):5-17. doi: 10.1038/s41375-022-01736-5. Epub 2022 Oct 29. Leukemia. 2023. PMID: 36309558 Review.
The treatment of chronic myeloid leukemia (CML) with tyrosine kinase inhibitors (TKIs) has been a model for cancer therapy development. Though most patients with CML have a normal quality and duration of life with TKI therapy, some patients progress to …
The treatment of chronic myeloid leukemia (CML) with tyrosine kinase inhibitors (TKIs) has been a model for cancer therapy …
Treatment of blast phase chronic myeloid leukaemia: A rare and challenging entity.
Copland M. Copland M. Br J Haematol. 2022 Dec;199(5):665-678. doi: 10.1111/bjh.18370. Epub 2022 Jul 22. Br J Haematol. 2022. PMID: 35866251 Free PMC article. Review.
Despite the success of BCR-ABL-specific tyrosine kinase inhibitors (TKIs) such as imatinib in chronic phase (CP) chronic myeloid leukaemia (CML), patients with blast phase (BP)-CML continue to have a dismal outcome with median survival of …
Despite the success of BCR-ABL-specific tyrosine kinase inhibitors (TKIs) such as imatinib in chronic phase (CP) chr …
Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
Deininger MW, Shah NP, Altman JK, Berman E, Bhatia R, Bhatnagar B, DeAngelo DJ, Gotlib J, Hobbs G, Maness L, Mead M, Metheny L, Mohan S, Moore JO, Naqvi K, Oehler V, Pallera AM, Patnaik M, Pratz K, Pusic I, Rose MG, Smith BD, Snyder DS, Sweet KL, Talpaz M, Thompson J, Yang DT, Gregory KM, Sundar H. Deininger MW, et al. J Natl Compr Canc Netw. 2020 Oct 1;18(10):1385-1415. doi: 10.6004/jnccn.2020.0047. J Natl Compr Canc Netw. 2020. PMID: 33022644
Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome (Ph) which results from a reciprocal translocation between chromosomes 9 and 22 [t(9;22] that gives rise to a BCR-ABL1 fusion gene. CML occurs in 3 different phases ( …
Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome (Ph) which results from a reciprocal tran …
Management of children and adolescents with chronic myeloid leukemia in blast phase: International pediatric CML expert panel recommendations.
Sembill S, Ampatzidou M, Chaudhury S, Dworzak M, Kalwak K, Karow A, Kiani A, Krumbholz M, Luesink M, Naumann-Bartsch N, De Moerloose B, Osborn M, Schultz KR, Sedlacek P, Giona F, Zwaan CM, Shimada H, Versluijs B, Millot F, Hijiya N, Suttorp M, Metzler M. Sembill S, et al. Leukemia. 2023 Mar;37(3):505-517. doi: 10.1038/s41375-023-01822-2. Epub 2023 Jan 27. Leukemia. 2023. PMID: 36707619 Free PMC article. Review.
Treatment of chronic myeloid leukemia has improved significantly with the introduction of tyrosine kinase inhibitors (TKIs), and treatment guidelines based on numerous clinical trials are available for chronic phase disease. However for CML in the b …
Treatment of chronic myeloid leukemia has improved significantly with the introduction of tyrosine kinase inhibitors (TKIs), a …
Management of TKI-resistant chronic phase CML.
Hughes TP, Shanmuganathan N. Hughes TP, et al. Hematology Am Soc Hematol Educ Program. 2022 Dec 9;2022(1):129-137. doi: 10.1182/hematology.2022000328. Hematology Am Soc Hematol Educ Program. 2022. PMID: 36485117 Free PMC article. Review.
Chronic phase CML (CP-CML) patients who are resistant to 2 or more tyrosine kinase inhibitors (TKIs) have limited therapeutic options and are at significant risk for progression to the blast phase. ...Emerging data suggest that a high dose of po …
Chronic phase CML (CP-CML) patients who are resistant to 2 or more tyrosine kinase inhibitors (TKIs) have limited therapeut …
Blast phase myeloproliferative neoplasm: contemporary review and 2024 treatment algorithm.
Tefferi A, Alkhateeb H, Gangat N. Tefferi A, et al. Blood Cancer J. 2023 Jul 18;13(1):108. doi: 10.1038/s41408-023-00878-8. Blood Cancer J. 2023. PMID: 37460550 Free PMC article. Review.
Leukemic transformation in myeloproliferative neoplasms (MPN), also referred to as "blast-phase MPN", is the most feared disease complication, with incidence estimates of 1-4% for essential thrombocythemia, 3-7% for polycythemia vera, and 9-13% for primary myelofibr …
Leukemic transformation in myeloproliferative neoplasms (MPN), also referred to as "blast-phase MPN", is the most feared disea …
Prognosis in Chronic Myeloid Leukemia: Baseline Factors, Dynamic Risk Assessment and Novel Insights.
Iezza M, Cortesi S, Ottaviani E, Mancini M, Venturi C, Monaldi C, De Santis S, Testoni N, Soverini S, Rosti G, Cavo M, Castagnetti F. Iezza M, et al. Cells. 2023 Jun 23;12(13):1703. doi: 10.3390/cells12131703. Cells. 2023. PMID: 37443737 Free PMC article. Review.
The introduction of tyrosine kinase inhibitors (TKIs) has changed the treatment paradigm of chronic myeloid leukemia (CML), leading to a dramatic improvement of the outcome of CML patients, who now have a nearly normal life expectancy and, in some selected cases, th …
The introduction of tyrosine kinase inhibitors (TKIs) has changed the treatment paradigm of chronic myeloid leukemia (CML), le …
An Update on the Management of Advanced Phase Chronic Myeloid Leukemia.
Short NJ, Senapati J, Jabbour E. Short NJ, et al. Curr Hematol Malig Rep. 2023 Dec;18(6):234-242. doi: 10.1007/s11899-023-00709-4. Epub 2023 Aug 31. Curr Hematol Malig Rep. 2023. PMID: 37651057 Review.
PURPOSE OF REVIEW: While most patients with chronic myeloid leukemia (CML) present in a chronic phase and are expected to have a normal life expectancy, some patients present with or progress to a more aggressive accelerated phase (AP) or bla …
PURPOSE OF REVIEW: While most patients with chronic myeloid leukemia (CML) present in a chronic phase and are ex …
Management of CML-blast crisis.
Hehlmann R, Saußele S, Voskanyan A, Silver RT. Hehlmann R, et al. Best Pract Res Clin Haematol. 2016 Sep;29(3):295-307. doi: 10.1016/j.beha.2016.10.005. Epub 2016 Oct 20. Best Pract Res Clin Haematol. 2016. PMID: 27839570 Review.
Management and Outcomes of Blast Transformed Chronic Myelomonocytic Leukemia.
Hammond D, Montalban-Bravo G. Hammond D, et al. Curr Hematol Malig Rep. 2021 Oct;16(5):405-417. doi: 10.1007/s11899-021-00643-3. Epub 2021 Sep 9. Curr Hematol Malig Rep. 2021. PMID: 34499330 Review.
PURPOSE OF REVIEW: Despite recent advances in the treatment of de novo acute myeloid leukemia (AML), AML arising from antecedent chronic myelomonocytic leukemia (CMML) continues to have dismal outcomes. ...Here, we review these biologic drivers, outcomes with …
PURPOSE OF REVIEW: Despite recent advances in the treatment of de novo acute myeloid leukemia (AML), AML arising from antecedent c …
202 results